Savara (NASDAQ:SVRA) Downgraded to "Sell" Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Savara (NASDAQ:SVRA) from a "hold" to a "sell" rating in a report issued Saturday.
• However, analysts overall remain constructive — MarketBeat shows a consensus rating of "Moderate Buy" with a $8.86 average price target and multiple firms issuing buy/overweight ratings and targets up to $10.
• Savara shares trade around $5.25 (50‑day $5.67, 200‑day $4.94) with a $1.07 billion market cap and negative EPS (consensus -$0.45 for the year); its lead candidate, Molgradex, is under regulatory review for autoimmune PAP.

Savara (NASDAQ:SVRA - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report issued on Saturday.

A number of other equities analysts have also commented on the stock. Guggenheim reiterated a "buy" rating on shares of Savara in a report on Tuesday, December 23rd. UBS Group set a $10.00 price objective on Savara in a report on Tuesday, December 23rd. Oppenheimer set a $10.00 target price on Savara in a research report on Tuesday, December 23rd. Wells Fargo & Company upped their price target on Savara from $7.00 to $9.00 and gave the company an "overweight" rating in a research report on Thursday, December 18th. Finally, HC Wainwright increased their price target on Savara from $8.00 to $10.00 and gave the company a "buy" rating in a research note on Tuesday, December 23rd. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $8.86.

Savara Stock Performance

Savara stock opened at $5.25 on Friday. The business has a 50 day moving average of $5.67 and a 200-day moving average of $4.94. The company has a market capitalization of $1.07 billion, a P/E ratio of -9.91 and a beta of 0.31. Savara has a 1 year low of $1.89 and a 1 year high of $7.01. The company has a debt-to-equity ratio of 0.32, a current ratio of 7.65 and a quick ratio of 7.65.

Savara (NASDAQ:SVRA - Get Free Report) last posted its earnings results on Friday, March 13th. The company reported ($0.13) EPS for the quarter. On average, equities research analysts predict that Savara will post -0.45 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Osaic Holdings Inc. boosted its position in shares of Savara by 6.9% during the 4th quarter. Osaic Holdings Inc. now owns 32,678 shares of the company's stock valued at $197,000 after purchasing an additional 2,098 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in Savara by 3.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 69,536 shares of the company's stock worth $420,000 after purchasing an additional 2,116 shares during the period. Graham Capital Management L.P. increased its holdings in Savara by 4.9% in the fourth quarter. Graham Capital Management L.P. now owns 56,013 shares of the company's stock worth $338,000 after purchasing an additional 2,615 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Savara by 9.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 33,155 shares of the company's stock worth $200,000 after purchasing an additional 2,859 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Savara by 48.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,887 shares of the company's stock valued at $60,000 after buying an additional 3,205 shares during the period. 87.93% of the stock is owned by institutional investors.

About Savara

Savara Inc NASDAQ: SVRA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.